The Experts Meetings on Psoriasis: Recommendations for Daily Practice

This retrospective study evaluated the safety and efficacy of tofacitinib, a Janus kinase 1/3 inhibitor, in 90 patients aged 18 or older with alopecia areata (AA) and at least 40% scalp hair loss. The primary endpoint was the percent change in the Severity of Alopecia Tool (SALT) score. Among 65 potential responders, 77% achieved a clinical response, with 58% showing greater than 50% improvement in SALT score over 4 to 18 months. Patients with AA had a higher percent change in SALT score compared to those with alopecia totalis or universalis (81.9% vs 59.0%). Tofacitinib was well tolerated with no serious adverse events. Despite limitations such as the study's retrospective nature, small sample size, and lack of a control group, tofacitinib showed promise for treating severe AA, alopecia totalis, and alopecia universalis, warranting further investigation through randomized controlled trials.